GE HealthCare reported fourth-quarter adjusted earnings of $1.44 per share, topping the consensus estimate of $1.40, on revenues of $5.69 billion versus expectations of $5.61 billion. Organic revenue growth reached 4.8%, contributing to total year‐over‐year sales growth of 7.1%. Net income attributable to the company was $589 million, down from $720 million in the prior year, reflecting a net income margin of 10.3%, a 320-basis-point decline compared with 13.5% in the year-ago period. Adjusted EBIT stood at $950 million, driving an adjusted EBIT margin of 16.7%, down 200 basis points from 18.7% a year earlier.

Imaging revenues rose 6.6% to $2.55 billion (5.3% organically), while Advanced Visualization Solutions delivered $1.53 billion in sales, up 5.9% (4.2% organically). Pharmaceutical Diagnostics posted the strongest growth, with revenues jumping 22.3% to $790 million (12.7% organically). Patient Care Solutions dipped 0.3% to $825 million. Both net income and EBIT margins were pressured by approximately $X00 million in tariff expenses and an unfavorable product mix, partially offset by volume gains and pricing actions. Total orders grew 2.0% organically, and the book-to-bill ratio remained healthy at 1.06.

For fiscal 2026, GE HealthCare forecasts adjusted earnings in the range of $4.95 to $5.15 per share, above the consensus of $4.92, and expects organic revenue growth of 3.0% to 4.0%. The company anticipates improvement in adjusted EBIT margin to between 15.8% and 16.1%, reflecting 50 to 80 basis points of expansion year-over-year. Management highlighted a differentiated innovation pipeline, continued capital investment in precision care technologies, and an expectation that tariff impacts will be reduced based on current trade rates. Free cash flow is targeted at approximately $1.7 billion, supported by a strong backlog and a robust balance sheet.